BioMed Realty Trust Inc. (BMR) Releases FY14 Earnings Guidance
BioMed Realty Trust Inc. (NYSE:BMR) issued an update on its FY14 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $1.50-1.54 for the period, compared to the Thomson Reuters consensus estimate of $1.50, AnalystRatingsNetwork.com reports.
BioMed Realty Trust Inc. (NYSE:BMR) traded down 1.34% during mid-day trading on Tuesday, hitting $21.29. 1,771,867 shares of the company’s stock traded hands. BioMed Realty Trust Inc. has a one year low of $17.90 and a one year high of $22.47. The stock has a 50-day moving average of $21.87 and a 200-day moving average of $20.89. The company has a market cap of $4.064 billion and a price-to-earnings ratio of 87.72.
BioMed Realty Trust (NYSE:BMR) last released its earnings data on Tuesday, August 5th. The company reported $0.40 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.36 by $0.04. The company had revenue of $171.16 million for the quarter, compared to the consensus estimate of $160.80 million. During the same quarter last year, the company posted $0.37 earnings per share. BioMed Realty Trust’s revenue was up 7.2% compared to the same quarter last year. Analysts expect that BioMed Realty Trust Inc. will post $1.50 EPS for the current fiscal year.
A number of analysts have recently weighed in on BMR shares. Analysts at Jefferies Group raised their price target on shares of BioMed Realty Trust from $23.00 to $25.00 in a research note on Tuesday, July 22nd. On a related note, analysts at MLV & Co
initiated coverage on shares of BioMed Realty Trust in a research note on Friday, June 27th. They set a hold rating and a $23.00 price target on the stock. Finally, analysts at Robert W. Baird raised their price target on shares of BioMed Realty Trust from $22.00 to $23.00 in a research note on Tuesday, May 13th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $23.14.
BioMed Realty Trust, Inc operates as a real estate investment trust (NYSE:BMR), and the general partner of BioMed Realty, L.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.